{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"18F-FSPG"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"18F-FDG"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Safety and tolerability of 18F-FSPG and 18F-FDG were assessed as treatment-related adverse events, and reported as the number of events related to each treatment, without dispersion.","groups":[{"description":"Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.\n\n18F-FSPG: Administered intravenously (IV)\n\n18F-FDG: Administered intravenously (IV)","id":"OG000","title":"18F-FSPG and 18F-FDG Intragroup Comparision"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline to up to 2 years","title":"Number of Treatment-Related Adverse Events","type":"SECONDARY","unitOfMeasure":"adverse events"}